Evgen Pharma Share Discussion Threads

[toffeeman] 22/8/2020 18:11

Yawn more regurgitation of old news - why do you bother MM?

[moneymunch] 22/8/2020 15:52

Potential transformational news stacking up.....SFX-01's phase 2 breast cancer results were outstanding .......news of their phase 2b trials coming soon and every chance of a commercial JV in the pipeline given that the results were "life changing for some patients"....exciting times...;-)





Rob Clarke Retweeted
Ed Tate
@TateScience
·
Jul 3

Read new #breastcancer research from @MCRBreastCentre with contributions from @tatescience & others, on targeting STAT3 signalling in ER+ breast cancers in @oncogenejournal



Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

......................

Rob Clarke
@RobClarkeLab
·
Jun 24
We’re looking for a talented student to carry out a PhD starting this September: Understanding the role of STAT3 in therapy-resistance and metastatic progression of breast cancer (MRC CASE) at The University of Manchester on hxxp://FindAPhD.com


About the Project

Resistance to endocrine and other therapies during metastatic progression is the major cause of mortality in breast cancer. We have previously reported that endocrine resistance can be driven by ALDH+ breast cancer stem cells (CSCs) and more recently that STAT3 is activated in these cells (Simoes et al., 2015 and 2020). We and others have reported that breast cancers resistant to the recently FDA-approved CDK4/6 inhibitors such as Palbociclib have increased numbers of CSCs and activation of STAT3 signalling, and that inflammatory and obesity-related breast cancer are driven by IL6 and leptin activating STAT3 transcriptional activity.

Our hypothesis is that targeting STAT3 would benefit breast cancer patients where CSCs are driven by the STAT3 signalling pathway, and in particular would combat therapy resistance and metastatic progression. In the Clarke lab, we have established in vitro and in vivo models of breast cancer patient-derived organoids and xenografts that metastasise to relevant organs such as lung and bone (Byrne et al., 2017, Eyre et al., 2019). The student will use these models to perform CSC assays, gene and protein expression analyses to characterise the signalling pathways targeted by SFX-01 and discover biomarkers that predict response.

The potential outcome is the definition of which breast cancers have STAT3 dependency and are sensitive to STAT3-targeted therapies. We aim to understand the mechanisms of STAT3 signalling and establish predictive biomarkers that will have translational value in precision medicine clinical trials, which the appointed student would help design during a placement in the iCASE partner company Evgen Pharma PLC, who aim to develop SFX-01 for improved breast cancer therapy.

[bumpa33] 21/8/2020 14:05

Yep, no other reason you’d think. Funny, same day I decide to start bugging Dundee Uni too. My ESP must be nicely in tune, for once..!

[moneymunch] 21/8/2020 13:57

Cheers Bumpa, it does look that way, otherwise why would Prof Chalmers put the tweet out...Gl ;-)

[bumpa33] 21/8/2020 13:54

Great find mm, we’re getting close :)

[moneymunch] 21/8/2020 13:49

DEFINE COVID-19

DEFINE is a clinical study which aims to test promising new therapies in small numbers of COVID-19 patients.

This clinical study will compare promising additional treatments against standard care (i.e. only treatments given routinely by your doctor/nurse) in patients who are experiencing different symptoms of COVID-19, either in the community or in a hospital environment. In order to assess how well the treatments are working, the study team will look at how safe and tolerable certain treatments are, and also measure small molecules in the blood and other samples called biomarkers. Biomarkers are molecules normally found in blood, other body fluids, or tissues and can be a sign of a normal or abnormal process, or of a condition or disease. In addition, knowing how certain biomarkers change (or not) with certain treatments will help us to understand how to tailor therapies for future COVID-19 patients.

The DEFINE clinical study is an Urgent Public Health (UPH) badged study which means this research will have an impact on public health within 12 months and that the science underpinning the proposed study is compelling.

You can learn more about the different aspects of the study by using the links below.

Visit the STOPCOVID webpages
Participant Information

The following documents contain information provided to participants in the DEFINE study.
DEFINE Participant Information Sheet (292.44 KB PDF)
DEFINE Participant Information Summary (147.91 KB PDF)


About the study
What is the purpose of the study?
Study timelines
Study design
Trial treatments
Taking part
Questions?

If you would like to ask about this study, please contact us.

Logos of DEFINE collaborators, including LifeArc, NHS Lothian and Accord.
Funders and collaborators

This adaptive trial platform is funded by LifeArc.

The study is sponsored by the University of Edinburgh and NHS Lothian through ACCORD.

The study has been given a favourable ethical opinion by the Scotland A ethics committee, the regulator and local Research and Development Departments.

[moneymunch] 21/8/2020 13:38

The article is 6 weeks old but Prof Chalmers Tweet is from today....;-)




ps Prof Chalmers and Prof Albena Dinkova-Kostova are the lead investigators for SFX-01's proposed Covid-19 patient trials.

[bocker01] 21/8/2020 13:30

Six weeks or so old already....

[moneymunch] 21/8/2020 13:16

SULSA

@SULSAtweets

·

30m

Today meet Prof Albena Dinkova-Kostova

@UoDMedicine

, collaborating with

@ProfJDChalmers

to study whether the anti-inflammatory Nrf2 activator sulforaphane can improve recovery and decrease the need for mechanical ventilation in patients with severe COVID-19 #ScotlandRespondsC19

1

2

SULSA

@SULSAtweets

·

Aug 20

Today say hello to Dr Annya Bruce

@EdinburghUni

who is part of DEFINE COVID-19, a clinical trial now recruiting, comparing treatments against standard care to identify biomarkers that could help tailor therapies for future patients #ScotlandRespondsC19

[hodhasharon] 21/8/2020 13:15

Calm ------ wait --------- Storm

[moneymunch] 21/8/2020 13:09

Scottish Universities Life Science Alliance

SULSA is a strategic alliance between eleven
Scottish Universities that aims to advance
Scotland’s research and innovation in the
life sciences

[moneymunch] 21/8/2020 13:06

Bingo.....ish....Gla ;-)


James D Chalmers Retweeted

SULSA

@SULSAtweets

·

19m

Today meet Prof Albena Dinkova-Kostova

@UoDMedicine

, collaborating with

@ProfJDChalmers

to study whether the anti-inflammatory Nrf2 activator sulforaphane can improve recovery and decrease the need for mechanical ventilation in patients with severe COVID-19 #ScotlandRespondsC19

[moneymunch] 21/8/2020 11:33

and every chance of plenty of upside and back to 15p plus in anticiaption....;-)

[moneymunch] 21/8/2020 10:40

Cheers Bumpa, i'll be amazed if we don't hear about the new CEO by month end and/or an update on proceedings. Gl ;-)

[bumpa33] 21/8/2020 10:25

Also been trying Dundee Uni, without much success, so far. Will update if I get anything.

[moneymunch] 21/8/2020 07:44

Maybe their work is done, with all share transfers done and loose ends tied, and with so much in the pipeline with SFX-01's development on multiple targets, one would have thought they would want a new CEO in place by the start of September. Gl ;-)

[bumpa33] 20/8/2020 16:41

Not much doing today, morning or afternoon.

[mesquida] 20/8/2020 14:29

Stock is well bid again this afternoon, it must be American interest.

[lovewinshatelosses] 20/8/2020 12:52

It will be my pleasure!

[bumpa33] 20/8/2020 11:50

lwhl - I’ll hold you to that...!

[bumpa33] 20/8/2020 11:44

C44 - agreed :)

Having read a lot about this now, the SAH trial seems a strange one to have gone for in the first place.

My impression of the outgoing CEO was perhaps that he was a bit too ‘nice’ and not nearly dynamic enough.

Striking a balance between under and over promoting oneself is tough, EVG definitely fall into the former category though. I don’t know why companies employ PR firms, most of them are utterly useless. I always recall someone telling me years ago that the dregs of ‘public school’ ended up in PR...! All these years later and I can’t disagree on that.

[lovewinshatelosses] 20/8/2020 11:23

It is not my job to defend the prospects and potential of the company - it is their job to do that and to deliver share holder value, something that the previous boss singularly failed to do. Good that his exit was not seemingly messy, but you cannot call his time at the helm a success, from the perspective of a shareholder!
You and Bumpa have done a better job of marketing the potential here than the company itself, which reflects badly on the company IMO.
I have been invested here since before the awful SAH results, held and indeed added further since then, as I said I would back in 2019, before said SAH results.
I am sufficiently interested in the SFX-01 breast cancer P11 results to risk a potential total wipe out - as I also said I would in earlier posts - but obviously I am more confident than pessimistic, or I would have already sold out and locked in a big loss.
I really, really want to be able to sing the praises of the management team here and I will be the first to do so if (and hopefully when) it is justified. I am not looking for a mere two or three bagger from my investment here. I may even buy you and Bumpa a few drinks to toast it, should that wonderful day/days come upon us:)